18FAl-NOTA-FAPI PET/CT Outperforms 18F-FDG PET/CT in Detecting Gastrointestinal Metastasis of Lobular Breast Carcinoma.
A 57-year-old woman with a history of right breast cancer surgery 22 years prior presented with CT findings of gastric and intestinal wall thickening, accompanied by mild-to-moderate FDG uptake on 18F
APA
Zhang A, Zu M, et al. (2026). 18FAl-NOTA-FAPI PET/CT Outperforms 18F-FDG PET/CT in Detecting Gastrointestinal Metastasis of Lobular Breast Carcinoma.. Clinical nuclear medicine, 51(3), e181-e182. https://doi.org/10.1097/RLU.0000000000006176
MLA
Zhang A, et al.. "18FAl-NOTA-FAPI PET/CT Outperforms 18F-FDG PET/CT in Detecting Gastrointestinal Metastasis of Lobular Breast Carcinoma.." Clinical nuclear medicine, vol. 51, no. 3, 2026, pp. e181-e182.
PMID
41632581
Abstract
A 57-year-old woman with a history of right breast cancer surgery 22 years prior presented with CT findings of gastric and intestinal wall thickening, accompanied by mild-to-moderate FDG uptake on 18F-FDG PET/CT. Pathological results showed lobular breast cancer metastasis. The lesions showed significantly higher uptake on 18FAl-NOTA-FAPI PET/CT, and an additional sternal metastasis was identified.
MeSH Terms
Humans; Positron Emission Tomography Computed Tomography; Middle Aged; Fluorodeoxyglucose F18; Female; Breast Neoplasms; Carcinoma, Lobular; Gastrointestinal Neoplasms; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring
같은 제1저자의 인용 많은 논문 (5)
- ChatGPT for improving postoperative instructions in multiple fields of plastic surgery.
- Melittin-Clonidine peritumoral injection gel for cold tumor: exposing tumor antigens and reducing immunosuppressive pressure on immune cells.
- Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patients.
- Polymorphisms of mismatch repair pathway genes predict clinical outcomes in acute myeloid leukemia patients.
- Nonglycosylated, Legumain-Cleavable ISACs Drive Potent Antitumor Immunotherapy via a Bystander Effect.